Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation

被引：12
作者：
Chan, Onyee [1 ,2 ]
Hunter, Anthony [1 ,2 ]
Talati, Chetasi [1 ]
Sallman, David A. [1 ,3 ]
Asghari, Hannah [1 ,2 ]
Song, Jinming [4 ]
Hussaini, Mohammad [4 ]
Bejanyan, Nelli [5 ]
Elmariah, Hany [5 ]
Kuykendall, Andrew T. [1 ]
Padron, Eric [2 ]
Komrokji, Rami S. [1 ,3 ,6 ]
List, Alan F. [1 ]
Lancet, Jeffrey E. [1 ]
Sweet, Kendra L. [1 ]
Mishra, Asmita [5 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Div Malignant Hematol, Tampa, FL USA
[2] Univ S Florida, Dept Med, Tampa, FL 33620 USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat & Cellular Immun, Tampa, FL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Div Malignant Hematol, Tampa, FL USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-131530
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
149
引用
收藏
页数：4
相关论文
共 50 条
  • [41] MORPHOLOGICAL FEATURES OF HEMATOPOIESIS IN MDS PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION WITH REDUCED INTENSITY CONDITIONING
    Dvirnyk, V.
    Kuzmina, L.
    Kokhno, A.
    Glasko, E.
    Parovichnikova, E.
    HAEMATOLOGICA, 2013, 98 : 580 - 580
  • [42] The outcome of allogeneic stem cell transplantation in patients with high risk MDS and AML: single center experience
    Halahleh, Khalid
    Odaily, Sarah
    Al Tell, Abdallah
    Al-Awabdeh, Tala
    Ma'kosa, Mohammad
    Najjar, Rula
    Rihani, Rawad
    Abu Shanab, Mayada
    Hussein, Nilly
    Khattab, Eman
    Sharma, Shanta
    Abu Khader, Ahmad
    Yousef, Dana
    Abu-Jazar, Husam
    Tbakhi, Abdelghani
    Sarhan, Mahmoud
    BONE MARROW TRANSPLANTATION, 2018, 53 : 189 - 190
  • [43] Allogeneic stem cell transplantation in MDS: reduced intensity conditioning and donor lymphocyte infusion
    Kroeger, N.
    LEUKEMIA RESEARCH, 2009, 33 : S28 - S28
  • [44] Impact of TP53 mutation on genetic and cellular hierarchy profile in complex karyotype AML/MDS with increased blasts
    Hwang, Jinha
    Kim, Ha Nui
    Kwon, Jung Ah
    Yoon, Soo-Young
    Jeon, Min Ji
    Yu, Eun Sang
    Kim, Dae Sik
    Choi, Chul Won
    Yoon, Jung
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [45] Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS
    Alatrash, Gheath
    Kidwell, Kelly M.
    Thall, Peter F.
    Di Stasi, Antonio
    Chen, Julianne
    Zope, Madhushree
    Crain, Alyssa K.
    Champlin, Richard E.
    Popat, Uday
    Shpall, Elizabeth J.
    Jones, Roy B.
    Andersson, Borje S.
    BONE MARROW TRANSPLANTATION, 2019, 54 (08) : 1245 - 1253
  • [46] Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS
    Gheath Alatrash
    Kelly M. Kidwell
    Peter F. Thall
    Antonio Di Stasi
    Julianne Chen
    Madhushree Zope
    Alyssa K. Crain
    Richard E. Champlin
    Uday Popat
    Elizabeth J. Shpall
    Roy B. Jones
    Borje S. Andersson
    Bone Marrow Transplantation, 2019, 54 : 1245 - 1253
  • [47] Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status
    Aldoss, Ibrahim
    Pham, Anh
    Li, Sierra Min
    Gendzekhadze, Ketevan
    Afkhami, Michelle
    Telatar, Milhan
    Hong, Hao
    Padeganeh, Abbas
    Bedell, Victoria
    Cao, Thai
    Khaled, Samer K.
    Al Malki, Monzr M.
    Salhotra, Amandeep
    Ali, Haris
    Aribi, Ahmed
    Palmer, Joycelynne
    Aoun, Patricia
    Spielberger, Ricardo
    Stein, Anthony S.
    Snyder, David
    O'Donnell, Margaret R.
    Murata-Collins, Joyce
    Senitzer, David
    Weisenburger, Dennis
    Forman, Stephen J.
    Pullarkat, Vinod
    Marcucci, Guido
    Pillai, Raju
    Nakamura, Ryotaro
    HAEMATOLOGICA, 2017, 102 (12) : 2030 - 2038
  • [48] Allogeneic stem cell transplantation for patients with myelodysplastic syndrome and aml after MDS (SAML): Superior results with reduced intensity versus standard conditioning
    Buchholz, S.
    Dammann, E.
    Dobbelstein, C.
    Stadler, M.
    Koenecke, C.
    Weissinger, E. M.
    Hertenstein, B.
    Krauter, J.
    Eder, M.
    Ganser, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 233 - 233
  • [49] Favorable Impact of Allogeneic Stem Cell Transplantation in Patients with Therapy-Related Myelodysplasia Regardless of TP53 Mutational Status
    Nakamura, Ryotaro
    Aldoss, Ibrahim
    Anh Pham
    Li, Sierra Min
    Gendzekhadze, Ketevan
    Afkhami, Michelle
    Telatar, Milhan
    Hong, Hao
    Padeganeh, Abbas
    Bedell, Victoria
    Thai Cao
    Khaled, Samer
    Al Malki, Monzr M.
    Salhotra, Amandeep
    Ali, Haris
    Aribi, Ahmed
    Palmer, Joycelynne M.
    Aoun, Patricia
    Spielberger, Ricardo
    Stein, Anthony S.
    Snyder, David S.
    O'Donnell, Margaret R.
    Murata-Collins, Joyce
    Senitzer, David
    Weisenburger, Dennis D.
    Forman, Stephen J.
    Pullarkat, Vinod
    Marcucci, Guido
    Pillai, Raju
    BLOOD, 2017, 130
  • [50] Allogeneic stem cell transplantation after chemotherapy and dose reduced-intensity conditioning for high-risk AML and MDS
    Schleuning, M
    Schmid, C
    Ledderose, G
    Tischer, J
    Weisser, M
    Humann, M
    Kolb, HJ
    BONE MARROW TRANSPLANTATION, 2003, 31 : S29 - S30
12345